Latest Articles
Genmab A/S (GMAB) Reports 50% Response Rate With Rina-S in Advanced Endometrial Cancer - Insider Monkey
Genmab A/S (GMAB) Reports 50% Response Rate With Rina-S in Advanced Endometrial Cancer Insider Monkey
Published: June 3, 2025, 5 a.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - BioSpace
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial BioSpace
Published: June 2, 2025, 11:48 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - GlobeNewswire
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial GlobeNewswire
Published: June 2, 2025, 6:32 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - Yahoo Finance
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial Yahoo Finance
Published: June 2, 2025, 6:30 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - Yahoo
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial Yahoo
Published: June 2, 2025, 6:30 p.m.
Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer - Medical Xpress
Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer Medical Xpress
Published: June 2, 2025, 6:20 p.m.
Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer | Newswise - Newswise
Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer | Newswise Newswise
Published: June 2, 2025, 2:25 p.m.
Cedars-Sinai Discusses the Latest Stroke Prevention Guidelines - BlackDoctor.org
Cedars-Sinai Discusses the Latest Stroke Prevention Guidelines BlackDoctor.org
Published: May 29, 2025, 6:04 p.m.
Embryo-derived trypsin-induced calcium entry is inhibited by endometrial infertility factor, LEFTY2 - Frontiers
Embryo-derived trypsin-induced calcium entry is inhibited by endometrial infertility factor, LEFTY2 Frontiers
Published: May 29, 2025, 9:37 a.m.
Real-World Analysis Informs Future Directions for Evaluating Dostarlimab/Chemotherapy in Advanced Endometrial Cancer - OncLive
Real-World Analysis Informs Future Directions for Evaluating Dostarlimab/Chemotherapy in Advanced Endometrial Cancer OncLive
Published: May 28, 2025, 2:28 p.m.
Link copied to clipboard!